ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the average ...

7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep. 18% of couples reported sleeping in separate rooms due to snoring and restlessness. Women report ...

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS growth were the result of increased demand for our sleep ...

ResMed Inc. (RMD), headquartered in San Diego, California, specializes in designing and delivering medical devices and cloud-connected software for the healthcare sector. With a market cap of $33.6 ...

ResMed has secured FDA clearance for its Personalized Therapy Comfort Settings (PTCS), branded as Smart Comfort - a significant step in sleep apnea treatment.

Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...

Medical device company ResMed (NYSE:RMD) in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit of $2.55 per share was 2.1% above analysts’ consensus estimates. Is now the ...

Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

Resmed RMD has received FDA clearance for Personalized Therapy Comfort Settings (“PTCS”), which will be marketed as Smart ...